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A B S T R A C T
Regeneration of β-cells by differentiation of pancreatic progenitor cells has the potential to fundamentally solve
the problems of the loss of β-cell function and mass during disease progression in both type 1 or 2 diabetes.
Therefore, discovery of novel differentiation inducers to promote islet regeneration is of great significance.
Pancreatic and duodenal homeobox1 (PDX-1) is a key transcription factor that promotes the development and
maturation of pancreatic β-cells. To screen potential novel small molecules for enhancing differentiation of
PNAC-1 cells, a human pancreatic ductal cell lines into insulin-producing cells (IPCs), we developed a high-
throughput screening method through fusing the PDX-1 promoter region with a luciferase reporter gene. We
screened and identified that andrographolide named C1037 stimulates PDX-1 expression in both mRNA and
protein level and significantly promotes PANC-1 cells differentiation into IPCs as compared with that of control
cells. The therapeutic effect of C037 in Streptozotocin induced diabetic mouse model through differentiation of
pancreatic ductal cells into insulin positive islets was also observed. Our study provides a novel method to screen
compounds regulating the differentiation of pancreatic progenitor cells having the potential of enhancing islet
regeneration for diabetes therapy.
1. Introduction
Diabetes mellitus is a major chronic disease and affecting millions of
people worldwide. According to the report of International Diabetes
Federation, the number of people with diabetes in the world reached to
463 million in 2019, and the prevalence of diabetes in adults aged
between 20 and 79 in China has reach to 116.4 million people in 2019.
The major reason that causes accumulation of diabetic population is
that insulin producing β-cells, which form bulk of islets (65–80%), are
targeted for destruction at early stage in type 1 diabetes and in the
progression of type 2 diabetes [1]. Therefore, loss of β-cell mass and
function is critical step in the development and also for targeted therapy
of both type 1 and type 2 diabetes. Currently, efforts are being made to
generate insulin-producing cells from stem cells or tissue specific pro-
genitor cells induced by various growth factors or genetic reprograming
[1–3], but no reports showed that pancreatic regeneration can be
achieved through induction of endogenous pancreatic stem cells/pro-
genitors by herbal extract or compounds. Therefore, identification of
novel and safe differentiation inducer is a prime requisite for islet
generation and increasing β-cell mass, which could be next generation
therapeutics for diabetes.
Pancreatic duodenal homeobox1 (PDX-1), encodes pancreatic duo-
denal homeoprotein 1, is a member of the ParaHox subfamily of
homeotic genes [4]. PDX-1 is a critical insulin transcription factor ex-
pressed by pancreatic β-cells, and is crucial in the early stage of pan-
creas development [5]. It regulates the expression of a variety of genes
involved in β-cell function, such as insulin, glucose transporter 2, glu-
cokinase and islet amyloid polypeptide [6]. Other studies have suc-
cessfully differentiated UCB-MSCs into IPCs by Adenovirus-mediated
expression of PDX-1 [3] or PDX-1 mRNA transfection [7]. These studies
indicate that PDX-1 is an important factor in regulating pancreatic-
endocrine differentiation, especially in the formation of functional β-
cells.
From a therapeutic perspective, the introduction by viral vector of
foreign genes has raised concerns about genome integration and tu-
morigenicity [8]. An attractive alternative is to use small molecules that
promote high expression of transcription factors to induce endogenous
pancreatic progenitor differentiation into mature and functional β-cells.
To screen compounds capable of up-regulating the expression of PDX-1,
we developed a high-throughput screening assay through fusing the
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PDX-1 promoter region with a luciferase reporter vector and screened
compounds using human pancreatic progenitor cell line, PANC-1 ductal
carcinoma cells. More than 400 extracted fractions of traditional herb
medicines were screened for the PDX-1 promoter activities, and as a
consequence, one of them named C754 extracted from Andrographis
paniculata could up-regulate PDX-1 expression in both mRNA and
protein levels, suggesting that C754 might induce PDX-1 expression
through either direct or indirect increasing of its promoter activity.
Further studies suggested that the compound andrographolide (C1037)
is the main active component of C754, and could facilitate PANC-1 cells
differentiation into functional insulin-producing cells compared with
that of control cells in in vitro model and therapeutic effect in STZ in-
duced type 1diabetic mice model through regeneration of insulin po-
sitive islets was also observed. Our current study, provide novel idea for
developing drug candidate for pancreatic islet regeneration through
inducing differentiation of pancreatic progenitor cells into insulin
producing cells.
2. Material and methods
2.1. Cell culture and differentiation
Human PANC-1 cells (Stem Cell Bank, Chinese Academy of Sciences,
Shanghai, China) were cultured in high-glucose DMEM (Hyclone,
ThermoFisher Scientific, MA, USA) supplemented with 10% fetal bo-
vine serum (FBS), 100 μg/mL of penicillin, and 100 μg/mL of strepto-
mycin. The medium was changed every alternate day. To induce PANC-
1 cells differentiation, basal culture medium was removed. After
washing with phosphate buffer (PBS) 3 times, the cells were digested
using 0.05% trypsin for 1 or 2 min to loosen the cells but not to detach
the cells from their extracellular matrix (ECM) and then cultured in
differentiation medium. Differentiation medium was DME/F12 medium
(ThermoFisher Scientific, MA, USA) containing 1% BSA and insulin
transferrin selenium (Sigma-Aldrich, MO, USA) [8]. Then PANC-1 cells
were cultured at 37 °C in a humidified chamber with 5% CO2. The
following criteria of the differentiation were used: 1) islet-like clusters
appear post-induction; 2) the islet-like clusters can be stained by DTZ,
3) expression islet specific genes like, insulin, PDX-1, and 4) secretion
insulin stimulated by higher glucose.
2.2. Animals and induction of hyperglycemia
All animal studies were approved by the Ethics committee of
Xiamen University. Eight weeks-old male Kunming mice, weighing
18–22 g (Beijing Weitong Lihua Experimental Animal Technology,
Beijing, China) were housed in Xiamen University Laboratory Animal
Center. Mice were raised on a 12 h light/dark cycle at room tempera-
ture with enough food and water. Mice were intraperitoneally (i.p.)
injected with STZ (150 mg/kg) in 0.1 M citrate buffer (pH 4.2–4.5) to
induce hyperglycemia. 3 days after STZ injection, blood glucose level
was measured with glucose meter (Roche, IN, USA) and mice with a
random blood glucose level up to 16.7 mM were regarded as type 1
diabetic mice (T1D).
2.3. Renal capsular transplantation
Mice were anesthetized with 10% hydration of chloral solution
(400 mg/kg). The 200 islets isolated from normal mice or 500 differ-
entiated islet-like cell clusters were handpicked under a dissection mi-
croscope to ensure islets of a similar size (~200 μm in diameter) were
selected and transplanted. Through the microcatheter, the cells were
injected into the renal capsular. The tip of the microcatheter was pre-
cisely moved during the implantation procedure and the injected cells
was folded and placed in the renal capsular. Blood glucose levels of
mice were monitored daily and recorded.
2.4. Treatment of C1037 on type 1 diabetes
The mice either injected with 0.1 M citrate buffer as a blank control
or injected STZ (Sigma-Aldrich, MO, USA) (150 mg/kg) in 0.1 M citrate
buffer (pH 4.2–4.5) to selectively destroy pancreatic β-cells to induce a
condition resembling type 1 diabetes (T1D). The onset of T1D/hy-
perglycemia was defined as fasting blood glucose levels ≥11.1 mmol/L
after 8 h of starvation and random blood glucose level ≥16.7 mmol/L.
The animals were randomly divided into 4 groups: 1). Blank control,
which is citrate buffer injected mice gavaged with saline solution; 2).
Negative control, T1D mice gavaged with saline solution; 3). Positive
control group, T1D mice injected with 180 μg/kg of liraglutide (Novo
Nordisk, Denmark); and 4). Treatment group, T1D mice gavaged with
50 mg/kg of C1037. All treatments were lasting for 40 days and blood
glucose was monitored every ten days.
2.5. Homeostasis model assessment (HOMA-B)
β-cell function was assessed by homeostasis model assessment
(HOMA), which was calculated as HOMA-B = 20 × FINS/(FPG-3.5) as
we did early[9].
2.6. RNA extraction and real-time RT-PCR (RT-qPCR)
Total RNA was extracted from cells using Trizol (ThermoFisher
Scientific, MA, USA). mRNA was reversed transcribed into cDNA using
the High-Capacity cDNA Reverse Transcription Kit (ThermoFisher
Scientific, MA, USA). cDNA primer sequences for β-actin, insulin, PDX-
1, glucagon, and PAX 6 were designed using IDT website (http://sg.
idtdna.com/site, CA, USA). The primer sequences were listed in Table
S1. Real-time qPCR reactions were performed with TaKaRa Taq™ Hot
Start Version (TaKaRa, Hong Kong, R007A).
2.7. Plasmid construction and transfection
The plasmids pENTER/PDX-1 and empty vector were purchased
from Vigene Biosciences corporation (Maryland, USA). Approximately
700 bp of human PDX-1 promoter sequence searched in Genecard
(http://www.genecards.org), amplified by PCR and excised with Nhe I/
Hind III and inserted into the Nhe I/Hind III site of pGL4.17 (Promega
Biotech, WI, USA) to generate the pPDX-1/luciferase (pPDX-1-Luc)
plasmid. The primer sequences for PDX-1 promoter were as follows:
forward, 5′-CTAGCTAGCCGAATGCCAGAGTTTCGT-GTGTT-3′, and re-
verse, 5′-CCCAAGCTTCTCCTCGCCGTTCATGGCT-3′. Transient trans-
fections were conducted with viafect Transfection Reagent (Promega,
WI, USA) according to the manufacturer’s instructions. Transfection
efficacy was reached to approximately 90% as monitored by co-
transfection of pEGFP-C1 vector with pENTER/PDX-1. And the trans-
fected cells were expended for Western blotting verification and for
differentiation study.
2.8. Lenti-PDX-1 construction and infection
2.8.1. Plasmid construction
We created the lentiCRISPRv2-PDX-1 plasmid by inserting gRNA
sequence targeting PDX-1 (5′-CGGCGAGGAGCAGTACTACG-3′) into
lentiCRISPRv2 vector through the restriction enzyme cutting site BsmBⅠ
according to the protocol from ZhangLab [10,11].
2.8.2. Lentivirus packaging and infection
293 T cells were seeded into 6-well plate the day before transfec-
tion. The following plasmids (1.5 μg lentiCRISPRv2-PDX-1, 0.75 μg
pMDL, 0.45 μg VSV-G and 0.3 μg REV) were mixed in 100 μL OPTI-
MEM, and 9 μL VigeneFection (Vigene Biosciences, Shandong, China)
was added in another 100 μL OPTI-MEM, incubate for 5 min. Mix the
VigeneFection mixture with plasmid mixture and incubate for 30 min.
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The culture medium of 293 T cells was changed with serum free
medium and then the transfection mixture was added into the wells, the
cells were incubated into 37 ℃, 5% CO2 incubator. Six hours later the
culture media was change with completed media and incubate for an-
other 48 h, the virus was harvested and stored at−80℃ for further use.
PANC-1 cells were seeded into 12-well plate and cultured to achieve
a confluence of 70%, the culture medium was discard before infection,
1 mL virus and 500 μL fresh medium were added, mix well and cultured
in 37 ℃ incubator, Twenty four hours later the medium was changed
and cells were cultured in media containing puromycin, 7–10 days
later, the cells were trypsinized and re-seeded to 96-well plate, single
colon of cells were expended for Western blotting verification and for
differentiation study.
2.9. Western blot analysis
Cells were lysed on ice with cell-lysis buffer (20 mM Tris-HCl
(pH8.0), 10 mmol/L EDTA, 137 mmol/L NaCl, 1% NP40, 10% glycerol,
100 mmol/L NaF, 1 mM PMSF, 1× Protease inhibitors cocktail, 1×
Phosphatase inhibitors cocktail, and 1 mM DTT). The concentration of
total protein was determined with BCA protein assay kit (Thermo
Scientific, MA, USA). Fifty microgram of total protein was separated by
10% SDS-PAGE and transferred to a PVDF membrane which was then
blocked with 5% milk. Antibodies used for Western blotting were rabbit
anti-PDX-1 antibody, mouse anti-tubulin antibody (Abcam, MA, USA),
goat anti-rabbit antibody and goat anti-mouse antibody (R&D, MN,
USA). Blots were developed using WesternBright ECL kit (Advansta, CA,
USA) according to the manufacturer’s instructions.
2.10. High-throughput screening
PANC-1 cells were plated into 6-well plate and cultured for over-
night and both pPDX-1-luc and Renilla luciferase plasmid were tran-
siently co-transfected with viafect Transfection Reagent (Promega, WI,
USA) according to the manufacturer’s instructions. 24 h post transfec-
tion, the cells were treated with compounds at a final concentration of
1.0 μM. Cells were incubated with compounds (Extracted compounds
from traditional Chinese herbal medicine, Haifeng Chen’s laboratory,
Xiamen University, China) for 2 days before the luciferase reporter
assay. Cells were then lysed and luciferase activity was assayed using
Dual-Luciferase® Reporter Assay System kit (Promega, WI, USA) fol-
lowing the manufacturer’s instructions.
2.11. Glucose stimulated insulin secretion assay
After differentiation, islet-like cell clusters were washed with PBS
buffer 3 times and then incubated for 1 h in KRB-LG (low glucose,
2.8 mM). 200 μL supernatant was collected and stored at 4 °C. The cells
were washed with PBS and treated for another 1 h in KRB-HG (High
glucose, 16.7 mM). 200 μL supernatant was collected and stored at 4 °C
for insulin concentration assay.
2.12. ELISA
The human insulin Immunoassay Kit (HKU Li Ka Shing Faculty of
Medicine, Hong Kong) was used to quantitatively determine insulin
concentrations in supernatant according to the manufacturer’s in-
structions. Briefly, 5 μL standards and sample were added to its re-
spective wells and incubated with 100 μL 1× Detection antibody so-
lution at room temperature for 90 min, shaking the plate at 600 rpm.
The plate was then washed 4 times with 300 μL 1× wash buffer. 100 μL
substrate solution was added to each well and incubated at room
temperature for 15 min out of light. After adding 100 μL stop solution to
each well, absorbance at 450 nm was measured immediately.
2.13. Homeostasis model assessment for β-cells function (HOMA-B)
HOMA-B assay was performed as we did previously [9]. Briefly, the
fasting plasma glucose and insulin levels were used to determine the
values of HOMA-B according to the following equations: HOMA-
B = (20 × FPI)/(FPG-3.5), where FPI is the fasting plasma insulin
concentration (mU/L) and FPG is the fasting plasma glucose level
(mmol/L).
2.14. Intraperitoneal glucose tolerance testing (IPGTT)
Mice were single-caged and fasted for 12 h prior to the injections.
Glucose (2 mg/g) was injected intraperitoneally. Blood glucose levels
were measured at 0, 20, 40, 60, 80, 100 min, and 120 min after glucose
injection.
2.15. Immunocytochemistry
Cells were fixed with 4% paraformaldehyde, and then permeated
with 0.1% Triton at room temperature. Non-specific sites were blocked
using 5% BSA for an additional 1 h. Cells were then incubated with
rabbit anti-PDX-1 antibody (Abcam, MA, USA) for 1 h. After washing 3
times with PBS buffer, cells were then stained with goat anti-rabbit
antibody labeled with FITC for another 1 h out of light. Images were
observed using a fluorescent microscope (Zesis, Germany).
2.16. Histology staining/or immunohistochemistry
Pancreatic tissue and kidney tissue were fixed by 4% paraf-
ormaldehyde for 24 h, dehydrated, embedded in paraffin and sectioned.
After dewaxing in xylene and rehydration in gradient ethanol, sections
were stained with hematoxylin and eosin. Or non-specific sites were
blocked using 5% BSA for an additional 1 h. Tissues were then in-
cubated with rabbit anti-insulin antibody (Abcam, MA, USA) for over-
night. After washing 3 times with PBS buffer, tissues were then stained
with goat anti-rabbit antibody labeled with HRP for another 1 h, after
washing, the slices were developed in Diaminobenzidine (DAB) solu-
tion, and then, the sections were observed by a microscope.
2.17. Statistical analysis
Data were analyzed with one-way ANOVA, using the Graphpad
program, and are expressed as mean ± standard error of mean (SEM).
Treatment differences were subjected to the Tukey’s test. Differences
were considered significant at p < 0.05.
3. Results
3.1. PANC-1 cells can be differentiated into functional insulin-producing
cells (IPCs)
PANC-1 is a cell line obtained from human pancreatic ductal car-
cinoma, expressing high levels of c-kit and stem cell factor (SCF), which
makes PANC-1 the most suitable model for progenitor studies.
However, as immortalized carcinoma derivatives, the PANC-1 cells may
not accurately reflect the biology of differentiation of normal cells, and
therefore, the results we got from PANC-1 were further confirmed in
vivo animal study. For inducing differentiation, the PANC-1 cells were
briefly exposed to trypsin to loosen rather than detach the cells from
their extracellular matrix (ECM), cells were then cultured in a serum
free medium. Within 24 h, the cell congregation can be observed and
the cell aggregation was more intense with the increase of differentia-
tion time. Islet-like cell clusters can be observed within 96 h, and
presented crimson red in color if stained by Dithizone (DTZ, Sigma-
Aldrich, MO, USA), a zinc-binding substance for staining islet (Fig. 1A).
RNA extracted from 6-day islet-like cell clusters demonstrated that
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insulin, glucagon and PAX6 were expressed at the transcription level
(Fig. 1B). To detect insulin secretion, cells were treated with either
2.8 mM or 16.7 mM of glucose and insulin in the supernatant was de-
tected by ELISA analysis. The results showed that insulin can be de-
tected from differentiated cells at both day 4 and day 6 in the super-
natant, however, the insulin secreted by cells at day 4 under the
stimulation of two different glucose concentrations showed no sig-
nificant difference, implying functionally immature although morpho-
logically like normal islets, while insulin level produced in the super-
natant from differentiated cells at day 6 stimulated with 16.7 mM of
glucose was significantly higher than those for cells with 2.8 mM glu-
cose, confirming a functional similarity to normal human islets
(Fig. 1C). For proving conceptually, whether IPCs, differentiated from
PANC-1 cells, survive and regulate blood glucose homeostasis in vivo,
STZ induced type 1 diabetic Kunming mice model, which is well ac-
cepted diabetic model, was established. As shown in Fig. 1D, the pan-
creatic islet from wild type mice were evenly dispersed and mostly oval
or round, the marginal lines of the islets were clear with no obvious
structural change as examined by H&E staining, strong and positive
insulin stain also can be found in immunofluorescence staining
(Fig. 1D), however, the islets in STZ treated mice were sparse, atrophic,
blurred and some of the islets were in a hollow state with inflammatory
cell infiltration. Immunofluorescence results showed that the insulin
expression in STZ treated mice decreased significantly with only a few
insulin particles were observed as compared with wild type mice. These
results demonstrated that i.p. injection of STZ caused damage of pan-
creatic islets, a typical phenomenon of type 1 diabetes. Transplantation
either the normal islet cells (Positive Control) isolated from pancreas of
normal mice or IPCs differentiated from PANC-1 cells under the renal
capsule, the blood glucose levels were reduced significantly at day one
after transplantation and the blood glucose was maintained in a normal
range in the next few days (Fig. 1E). Mice in positive control group and
IPCs group were sacrificed 5 days after transplantation, H&E staining
and immunofluorescence staining were carried out to observe the state
of the IPCs under the renal capsule. IPCs were evenly distributed in the
kidney tissue and produced insulin (Fig. 1F), which demonstrated that
IPCs can survive and were functional to produce insulin in vivo to
maintain the homostasis of blood glucose level. These results demon-
strated that the method for differentiation PANC-1 cells into functional
insulin producing cells has been established.
3.2. PDX-1 plays critical role in PANC-1 differentiation into insulin-
producing cells
To investigate the functional role of PDX-1 during the differentia-
tion of PANC-1 into IPCs, immunoblot study was carried out from 0 h to
96 h in clusters of differentiating PANC-1 cells. The results showed that
PDX-1 expression was increased about 32% within 12 h of differ-
entiation and decreased continuously as time prolonged (Fig. 2A, B).
Furthermore, PDX-1 was translocated from the cytoplasm to the nucleus
Fig. 1. PANC-1 cells can be differentiated into functional insulin producing cells. PANC-1 cells were differentiated in defined media, and (A) Representative bright
field image of cells under differentiation for 0 h, 12 h, 24 h, 48 h, 72 h, 96 h and observed at 10× magnification, dithizone stained cell clusters on day 4th and
observed at 5× magnification (n = 3); (B) Representative results shown that at day 6 of exposure to SFM/ITS, expression of the transcripts for insulin, glucagon, and
Pax-6 in differentiated cells (n = 3); (C) Concentrations of insulin on day 0, day 4 and day 6 induced either 2.8 mM or 16.7 mM glucose respectively. *p < 0.05,
**p < 0.01 vs control; ##p < 0.01 16.7 mM compared to 2.8 mM of glucose; Δp < 0.05 Day 6 compared to Day 4. Results were expressed as mean ± SD of three
independent experiments; (D) for transplantation of insulin producing cells (IPCs) differentiated from PANC-1 cells, the animals were separated into four groups: WT
(litter mate mice, without any treatment), Sham operation (WT + sham operation), Positive control (Diabetes + Islet isolated from WT mice), Islet-like clusters
(Diabetes + IPCs). Representative histology and immunofluorescence image of pancreases from wild type and STZ-induced mice, respectively (n = 5) were shown;
(E) Random blood glucose level post transplantation. ***p < 0.01 vs sham operation. Results were expressed as Mean ± SEM of five animals in each group; (F)
Representative histology and immunofluorescence image of renal capsular of mice transplanted with normal mouse islets (positive control) or insulin-producing cells
differentiated from PANC-1 cells (n = 5) were shown.
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Fig. 2. Important role of PDX-1 in PANC-1 cells dif-
ferentiation into IPCs. (A, B) Representative Western
blot images and protein expression of PDX-1 in in-
duced cell clusters at 0 h, 12 h, 24 h, 48 h, 72 h, 96 h
respectively (n = 3 per time point), RD: Relative
Density vs β-tubulin; (C) Representative immuno-
fluorescent images showing the localization of PDX-1
in cell clusters under differentiation for 0 h, 12 h,
24 h, 48 h, 72 h, 96 h (n = 3 per time point); (D, E)
Representative Western blot images and protein ex-
pression of PDX-1 in PANC-1 cells transfected with
either empty vector (Vector) or pPDX-1, RD: Relative
Density vs β-tubulin; (F) Representative bright field
images showing the morphology of differentiated
PANC-1 cells at 0 h, 12 h, 24 h, 48 h, 96 h (n = 3 per
time point); (G) RT-qPCR analysis of pancreas for the
expression of relevant genes (insulin, glucagon, PAX
6) in different time point post-differentiation.
*p < 0.05 pPDX-1 group vs Vector group. Results
were expressed as mean ± SD of three independent
experiments; (H) Concentrations of insulin in vector
or pPDX-1 group on day 0, and day 4 induced with
2.8 mM and 16.7 mM glucose respectively.
*p < 0.05 16.7 mM of glucose vs 2.8 mM of glucose
in PDX-1 over-expressed groups. Results were ex-
pressed as mean ± SEM of three independent ex-
periments; (I, J) Representative Western blot images
and protein expression of PDX-1 in PANC-1 cells in-
fected either with control (Con) or Lenti-PDX-1
(n = 3 per group), RD: Relative Density vs β-tubulin;
(K) Representative bright field images shown the
morphology of differentiated PANC-1 cells at 0 h,
12 h, 24 h, 48 h, 96 h (n = 3 per time point).
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in the early stages of differentiation and subsequently translocated from
the nucleus back into the cytoplasm as shown in immunofluorescence
stain (Fig. 2C), indicating that PDX-1 is likely involved in initiating
PANC-1 differentiation. To further evaluate the efficacy of PDX-1 on
PANC-1 differentiation into IPCs, PANC-1 cells were transfected either
with pcDNA3.1-PDX-1 or pcDNA3.1 plasmid (Vector control). Com-
pared with vector control, relative higher expression of PDX-1 was
observed in PDX-1 transfected cells (Fig. 2D, E). PANC-1 cells trans-
fected with either empty vector or PDX-1 were cultured in complete
media at day 0 and then subjected to differentiation using SFM/ITS.
The morphology of differentiated PANC-1 cells in both groups were
observed at 0 h, 12 h, 24 h, 48 h and 96 h, and results showed that,
compared to vector control, more islet-like cell clusters in PDX-1
overexpressed groups were observed (Fig. 2F). Differences in expression
of insulin, glucagon, PAX6 between the groups in successive time points
were tested by RT-qPCR (Fig. 2G). In comparison with the vector group,
cells in the pPDX-1 expressing group showed higher expression of in-
sulin and glucagon, with no significant change in PAX 6 expression. To
further determine the efficiency of differentiation, differentiated cells at
96 h in both groups were stimulated with 2.8 mM or 16.7 mM of glu-
cose. At both concentrations, cells induced in either groups produced
insulin in the supernatant. However, the amount of insulin secreted by
cells in the vector group showed no significant difference between the
two glucose conditions, presuming that cells in vector group did not
fully differentiate into mature islet-like cell clusters within 96 h, while
the insulin concentrations produced by cells in pPDX-1 expressed group
were higher than those cells in the vector group upon stimulation by
16.7 mM of glucose compared to 2.8 mM (Fig. 2H). To further confirm
whether down-modulation expression of PDX-1 affect PANC-1 cells
differentiates into IPCs, the PANC-1 cells were infected by lentivirus
carried PDX-1 gRNA. Knock-out efficacy was evaluated by Western blot,
as shown in Fig. 2I, J, Lenti-PDX-1 significantly down-regulated ex-
pression of PDX-1, and as a consequence, the differentiation of PANC-1
cells into IPCs was abolished completely at 96 h (Fig. 2K). The results
from the gain-of-function as well as loss-of-function experiments in-
dicate that PDX-1 plays a critical role in the differentiation of PNAC-1
into IPCs.
3.3. Designing a high-throughput (HTP) screen model and compounds
screening.
As PDX-1 plays critical role in the differentiation of PANC-1 cells
into IPCs. Therefore, we wish to screen compounds that accelerate the
differentiation of PANC-1 cells through up-regulating of PDX-1 ex-
pression. Therefore, we developed a high-throughput screen assay by
fusing the PDX-1 promoter region with a firefly luciferase reporter
vector named pGL3.14 to generate pPDX-1-Luc vector (Fig. 3A).
Fluorescence value, which represents the ability of compounds in in-
creasing PDX-1 promoter activity, from PANC-1 cells extracts induced
by different compounds was measured. More than 400 extracted frac-
tions of herbal medicines were screened and the enhancement ratio by
each compound was calculated based on the fluorescence value
(Fig. 3B). Eleven fractions (Fig. 3B, red cycle) with high enhancement
ratios were selected to further validate their activity on PDX-1 expres-
sion. After 24 h being treated with compounds, RNA was isolated from
PANC-1 cells to assess the ability of compounds to upregulate en-
dogenous PDX-1 expression. Results showed that C421, C582, C713,
C754, C807 could slightly increase PDX-1 gene expression (Fig. 3C). In
addition, the effects of C421, C582, C713, C754 and C807 on PDX-1
protein were assessed, and results shown that C582, C713, C754, C807
significantly increased the expression of PDX-1 at protein level (Fig. 3D,
E). Since it has been reported that Andrographis paniculata a traditional
Chinese herb medicine has anti-diabetic effect [12,13], thus, C754, a
extracted fraction of Andrographis paniculata was selected for further
study.
3.4. C1037 is the active ingredient of C754.
To screen out the active ingredients of C754, C754 was analyzed by
HPLC-HR-MS. The total ion chromatogram (TIC) of C754 gave the
characteristic pseudo-molecular ion peak at tR = 8.7, 701.4251 ([2 M
+H]+) and 351.2161 ([M+H]+) in positive mode (Fig. 4A, B, D),
which was in accordance with the retention time and molecular for-
mula C20H30O5 of reference standard andrographolide (C1037)
(Fig. 4C, E). Thus, C1037, as one of the main components of C754, was
further investigated for its regulation capbility of PDX-1 promoter ac-
tivities.
Consistent with C754, the expression of PDX-1 in cells treated with
different concentrations of C1037 (1.25 μM, 2.5 μM, 5.0 μM) was sig-
nificantly upregulated in a dose-dependent manner as shown in luci-
ferase assay (Fig. 5A). In accordance with the luciferase results, the
PDX-1 mRNA (Fig. 5B) and protein levels (Fig. 5C, D) were also induced
by C1037 in a dose-dependent manner.
3.5. C1037 accelerates PANC-1 cells differentiation into IPCs
To test whether C1037 could promote differentiation of PANC-1
cells into insulin-producing cells, PANC-1 cells were subjected to SFM/
ITS with or without C1037 and microscopically observations were re-
corded in time-dependent manner. In both groups, PANC-1 cells form
cell clusters that resembled islets after 96 h of culture. However, dif-
ferent condensation patterns were noticed between two groups, with
cells in C1037 treatment triggering earlier cell cluster formation
(Fig. 6A). By detecting the islet-relevant gene (insulin, glucagon, PAX 6)
expression, we found that cells induced with C1037 showed higher
expression of insulin and lower expression of glucagon, with no sig-
nificant change in PAX 6 expression (Fig. 6B), indicating that the pro-
portion of β-cells in differentiated cells with C1037 treatment was more
robust and the proportion of α-cells was less than that of control cells.
Glucose stimulated insulin secretion results showed that at both con-
centrations of glucose, cells in two groups produced insulin in the su-
pernatant. However, the amount of insulin secreted by cells in control
group showed no significant difference between the two concentrations
of glucose. The insulin concentrations expressed by cells in C1037 in-
duced group were higher than those for cells in control group, and
secreted more insulin stimulated by 16.7 mM glucose compared with
2.8 mM glucose treatment (Fig. 6C). Therefore C1037 promotes the
PANC-1 differentiation into matured insulin producing cells.
3.6. C1037 treatment restores glucose homeostasis in type 1 diabetic mice
In order to test whether C1037 has therapeutic effect in diabetic
animal model, type 1 diabetic (T1D) mice induced by STZ were treated
with saline, Liraglutide or C1037, citrate buffer injected mice were used
as blank control. Results showing that compared with blank control, the
blood glucose level in saline group is significantly higher
(##p < 0.01). While compared with saline group, the blood glucose
levels both in liraglutide treated group (**p < 0.01) and C1037
treated group (*p < 0.05) decreased significantly starting from day 10
and lasting till the end of experiments (Fig. 7A). The body weights were
similar among different groups of mice except significantly lower in
saline group compared with blank control on day 20 (#p < 0.05), 30
(##p < 0.01), and 40 (##p < 0.01) (Fig. 7B). To determine the un-
derlying cause of reducing blood glucose by C1037, the mice were then
performed with intraperitoneal glucose tolerance test (IPGTT) test, at
about 20 min after a glucose injection (2 g/kg) into peritoneal cavity of
mice that were fasted for 16 h, the blood glucose levels were increased
in both liraglutide and C1037 treated group, and then decreased, the
courses were comparable with blank control, but significantly lower
compared to saline group at 40 (*p < 0.05), 60 (*p < 0.05), 80
(*p < 0.05) and 120 min (**p < 0.01) in liraglutide treated group
and at 80 (*p < 0.05), 100(*p < 0.05), 120 min (*p < 0.05) in
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C1037 treated group (Fig. 7C), indicating that glucose homostasis was
restored in both liraglutide and C1037 treated group. To further de-
termine whether this phenomena was related with restored β-cell
function, the HOMA-B was assessed, compared to blank control, the
HOMA-B score was significantly lower in saline group (#p < 0.05),
while compared to saline group, the HOMA-B score was significantly
increased in both liraglutide and C1037 treated groups (Fig. 7D,
*p < 0.05). These results demonstrating β-cell function is abnormal in
sanline group, while restored in both liraglutide and C1037 treated
groups.
3.7. Treatment with C1037 enhances PDX-1 positive islets, restores
morphology of pancreas, and increases insulin positive islets in type 1
diabetic mice
Since treatment of C1037 significantly decreases blood glucose level
and increase HOMA-B score, we wondered if this is related to enhanced
expression of PDX-1 and restored insulin positive islets morphology in
T1D mice, the immunofluorescent staining, H & E stain and im-
munohistochemistry analysis were performed. Results shown that
compared with control, less and disrupted islets were found in H & E
stain of 20× or 200× magnification in saline group, while compared
with saline group, the number and morphology of islet in both lir-
aglutide or C1037 treated group were restored (Fig. 9A). It was further
confirmed by immunohistochemistry stain that, compared with control,
less and destruction insulin positive islets were observed in saline
group, whereas the number of PDX-1 positive islets (Fig. 8) and insulin
positive islets are increased in both liraglutide or C1037 treated groups,
compared with saline group (Fig. 9B).
Fig. 3. C754 induces PDX-1 gene and protein expression. (A) Establishment of HTP screening model through fusing the PDX-1 promoter region with a luciferase
reporter vector; (B) The enhancement ratio of each compound, scored relative to control cells treated with DMSO; (C) RT-PCR analysis of PDX-1 expression in PANC-
1cells induced by selected compounds for 24 h. GAPDH was used as a loading control; (D, E) Representative Western blot images and protein expression of PDX-1 in
PANC-1 cells treated with selected compounds for 48 h. Tubulin was used as an internal loading control. Results were expressed as mean ± SD of three independent
experiments, RD: Relative Density vs β-tubulin.
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4. Discussion
Diabetes is a non-infective chronic disease, affecting about 463
million populations worldwide and 116.4 million people in China in
2019 [14]. The loss of β-cell mass and function is critical in the pro-
gression of both type 1 and advanced type 2 diabetes. Currently, var-
ious strategies have been developed to promote recovery of the β-cell
mass, like bioartificial pancreas [15], nanotechnology to encapsulation
incretin to protecting and regeneration of β-cell [16], alpha-cell to beta-
cell transdifferentiation [17,18], and differentiation of embryonic stem
cells or multipotent stem cells into insulin-producing cells, providing
novel ideas for cell replacement and treatment of diabetes [19].
The stem cells that have the potential to differentiate into insulin-
secreting cells include embryonic stem cells, and adult stem cells or
mesenchymal stem cells derived from various tissues such as pancreas,
liver, central nervous system, bone marrow, adipose tissue, etc.
[20,21]. Recently, methods for differentiation non-β-cells into insulin
producing cells through induction or genetic reprograming provide a
novel idea for diabetes treatment [22–25], and many transcription
factors related with pancreas development were overexpressed to reg-
ulate β-cells differentiation (mainly PDX-1).
PDX-1, also known as insulin promoter 1, is an important tran-
scription factor for normal pancreatic development and islet β-cell
differentiation and maturation. In fact, in addition to the absence of
Fig. 4. HPLC-HR-MS analysis of C754 and C1037. (A) Total ion chromatogram (TIC) of C754 in positive mode; (B) Total ion chromatogram (TIC) of C1037 in positive
mode; (C) The MS spectrum of C1037; (D) The elemental composition analysis of the peak at tR = 8.7 min; (E) The chemical structure of C1037.
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Bruner’s glands and the lack of intestinal endocrine differentiation in
the stomach and duodenum, heterozygous Pdx1+/- mice exhibited an
age-dependent deterioration of glucose tolerance, reduced glucose-sti-
mulated insulin secretion and higher apoptosis sensitivity [6]. Ad-
ditionally, PDX1-/- knockout mice also showed loss of pancreatic for-
mation [5].
The expression of PDX-1 plays an important role in inducing dif-
ferentiation of stem cells derived from different tissue sources into in-
sulin producing cells (IPCs). Studies showed that after removing most of
the pancreas, new islets were found in the surrounding of remaining
cells and pancreatic duct epithelial cells, and the newly born islets were
mainly derived from the differentiation of pancreatic ductal epithelial
stem cells under the action of PDX1 [26]. This process is similar to that
of embryonic development. During embryonic development, the liver
and pancreas can be trans-differentiated in certain conditions from
pancreatic endocrine precursor cells in the liver, through expression of
insulin transcriptional factors related to the development of pancreatic
endocrine cells, such as HNF, PDX-1, and Ngn3, and so on [27]. Ad-
ditionally, PDX-1 has been used as a reprogramming factor to trigger
various sources of mesenchymal stem cells and embryonic stem cells to
differentiate into endocrine pancreatic cells [28–32]. PDX-1 over-
expression induces liver stem cells to differentiate into IPCs [27]. Yang
et al. [33] confirmed that the fusion gene PDX1-VP16 induced the liver
stem cell line (WB-1 cells) into cells that produce and secrete insulin.
Consistent with these studies, we also observed that PDX-1 plays critical
role in the differentiation of PANC-1 cells into IPCs (Fig. 1).
Therefore, we aimed to identify small molecules capable of pro-
moting pancreatic duct cells differentiation into insulin producing cells
through enhancing the expression of the transcription factor PDX1.
First, we observed that expression level and pattern of PDX-1 is changed
during the differentiation of PANC-1 cell. Transfection of PANC-1 cells
with PDX-1, followed by SFM/ITS culture, accelerates phenotypic
changes towards insulin producing cells (IPCs, Fig. 2D, E, F, G, H),
while down-modulation of PDX-1 expression abolished differentiation
of PANC-1 into IPCs (Fig. 2I, J, K), which is consistent with previous
report on the critical role of PDX-1 in pancreatic β-cell development
[31,32].
We then establishment a High-Throughput Screening (HTS) assay
by fusing PDX-1 promoter region to a luciferase reporter vector and
performed compounds screening to identify compounds capable of up-
regulating PDX-1 expression. From 400 herbal extracted fractions of
herbal medicines, C754, an extracted fraction from Andrographis pani-
culata, which could significantly increase the PDX-1 expression, was
identified and analysed (Fig. 3). Then HPLC-MS were performed to
identify the active ingredients within C754. Results showed that the
molecular weight of the main components in C754 was 350 Da, con-
sistent with that of our predicted compound, andrographolide. After
analysis in the same chromatographic condition, the molecule marked
with Peak 1 and andrographolide standard have same retention time,
indicating that the molecule marked with Peak 1 is andrographolide
(C1037) (Fig. 4).
We then further confirmed that C1037 induces PDX-1 expression
both at transcript and protein levels in PANC-1 cells in a dose-depen-
dent manner (Fig. 5). Treatment with C1037 enhanced differentiation
and maturation of PANC-1 into IPCs, as indicated by inducing expres-
sions of several genes related to β-cells (PDX-1, insulin, Pax6), and
could produce more insulin in the supernatant stimulated by glucose
(Fig. 6). To further assess whether C1037 has therapeutic effect on type
1 diabetic (T1D) mice, single higher doses of β-cell toxin streptozotocin
(STZ, at 150 mg/kg) was intraperitoneal (i.p.) injected into mice to
induced T1D mice model [34,35]. The blood glucose level was elevated
above 16.7 mM (Fig. 7A), function of β-cells was lost (Fig. 7D) and
Fig. 5. C1037 up-regulates expression of PDX-1. (A) Luciferase activity in PANC-1 cells treated with C1037 in indicated concentration. ####p < 0.0001 vs vector
control; **p < 0.01 vs DMSO; (B) RT-qPCR analysis of PDX-1 expression in PANC-1 cells induced by C1037 for 96 h. The fold change was scored relative to control
cells treated with DMSO. *p < 0.05 vs DMSO; (C, D) Representative Western blot images and protein expression of PDX-1 in PANC-1 cells treated with C1037 for
48 h. Tubulin was used as an internal loading control. Results were expressed as mean ± SD of three independent experiments. RD: Relative Density vs β-tubulin.
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existing pancreatic islet was destructed (Fig. 9A). Because liraglutide is
the only drug capable of improving glycaemic control [36,37] and in-
ducing neogenesis of β-cells as the clinical anti-diabetic drug [38,39], it
was thus used as a positive control, and as evidenced from our
experiments, compared to saline group, significantly decreased blood
glucose level (Fig. 7A) in T1D mice treated with 180 μg/kg of liraglu-
tide was observed 10 days after treatment and lasting till 40 days with
increased β-cell function (Fig. 7D), restored islet morphology (Fig. 9A),
Fig. 6. C1037 induces PANC-1 cells differentiation into functional insulin-producing cells. (A) Representative bright field image of cells induced with or without
C1037 treatment under differentiation for 12 h, 24 h, 48 h, 72 h, 96 h at 10× magnification; (B) RT-qPCR analysis of pancreas related genes (insulin, glucagon, PAX
6) expression in a time-dependent manner. *p < 0.05, C1037 treated group compared to non-treated group. Results were expressed as mean ± SD of three
independent experiments; (C) Concentrations of insulin in cells with or without C1037 treatment on day 4 induced with 2.8 mM and 16.7 mM glucose respectively.
*p < 0.05, C1037 treated group compared to non-treated group, #p < 0.05, 16.7 mM of glucose compared to 2.8 mM of glucose treated group. Results were
expressed as mean ± SD of three independent experiments.
Fig. 7. Therapeutic effect of C1037 on
type 1 Diabetes. STZ induced type 1
diabetes mice were separated into three
groups: saline (Diabetes + saline);
Liraglutide (diabetes + liraglutide),
and C1037 (diabetes + C1037), and
untreated litter mate mice were used as
control (non diabetes), Control and
saline groups of mice were treated with
saline, and 180 μg/kg of liraglutide (i.p)
or 50 mg/Kg of C1037 treated to the
mice for 40 days and blood glucose
level (A), body weight (B) were mon-
itored. At end of treatment, in-
traperitoneal glucose tolerance test
(IPGTT) test (C), and HOMA-B (D) were
performed. #p < 0.05 compared to
blank control, *p < 0.05, and
**p < 0.01 compared to saline group.
Results were expressed as
mean ± SEM of six animals in each
groups.
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and increased number of insulin producing cells (Fig. 9B). Similarly,
compared with saline group, lower blood glucose level in T1D mice
(Fig. 7A), and decreased blood glucose level in IPGTT test (Fig. 7C) was
also observed in C1037 treated group. We further tested weather ob-
served lower blood glucose effect by C1037 is related with increased
number of PDX-1 positive islet and recovery of β-cell function, im-
munofluorescent staining was performed in the pancreas from different
group. Results shown that the number of PDX-1 positive islets were
significantly increased in C1037 treated group compared either saline
group or liraglutide group (Fig. 8). As compared to saline group, the
function of β-cells in C1037 treated group were restored as indicated by
increasing HOMA-B score (Fig. 7D). We further observed that, as
compared with saline group, in which the morphology of islet was
disrupted (Fig. 9A), the number of islets (Fig. 9A, B, 20× magnifica-
tion) and insulin positive stains were decreased (Fig. 9B), increased
number of islets (Fig. 9A, B, 20× magnification), restored islet mor-
phology (Fig. 9A, 200× magnification), and increased insulin positive
islets (Fig. 9B, 200× magnification) were observed in T1D mice treated
with C1037, indicating that regeneration of β-cells were induced by
C1037 treatment in vivo, which is constant with early report that an-
drographolide prevents development of autoimmune diabetes in NOD
mice [12] and hypoglycemic and protects β-cells from H2O2 and other
reactive oxidative species-induced damage [13]. However, since re-
generation of pancreatic islets and β-cells could be achieved by pro-
liferation of existing β-cells [40], by neogenesis from α-cells [41,42], or
by regeneration from endogenous progenitors [43] or duct-progenitors
[44,45], we are unable to identify exactly where the newly generated
islets or insulin positive cells came from in our current study, but
considering the data from in vitro study, PANC-1 cell, a human pan-
creatic ductal progenitors, can be enhanced to differentiate into func-
tional insulin producing cells (Fig. 6) by C1037, therefore, more likely,
the regenerated islets or insulin positive cells in animal study may come
from differentiation of pancreatic ductal progenitors, which will need to
be experimentally validated by future study.
Overall, for the first time, our current study developed a new
method for screening compounds that regulate the expression of PDX-1
as a surrogate to identify differentiation inducers to promote islet re-
generation. Simultaneously, we identified and functionally character-
ized compound C1037, which could accelerate PANC-1 cells differ-
entiation through up-regulating the expression of PDX-1 in vitro, and
inducing expression of PDX-1 in pancreas of T1D mice, showing a
promising for diabetes treatment, especially for type 1 diabetes.
Fig. 8. Treatment with C1037 increases number of PDX-1 positive islets in type 1 diabetic mice. The pancreas of the different group of mice from Fig. 7 were analysed
by immunofluorescent stain, and representative immunofluorescent image in the pancreas from different groups were shown (A, and the number of PDX-1 positive
islets were counted and analyzed (B). ##p < 0.01 vs Control; ***p < 0.001 vs Saline group; &&p < 0.01 vs Liraglutide group (n = 3 per group).
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However, these anti-diabetic effects of C1037 are still preliminary, and
future pre-clinical and clinical examinations should be needed to ensure
the safety and efficacy of C1037 for development as a drug lead can-
didate.
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